The initial public offering (IPO) of Akums Drugs and Pharma is now open for subscription; Should you invest?
Akums Drugs and Pharma IPO Subscription Day 1: The initial public offering (IPO) of Akums Drugs and Pharma is now open for subscription. The issue closes on August 1. The company plans to raise around Rs 1857 crore through the public offer. Here are 10 things to know about the Akums Drugs and Pharma IPO before subscribing to the issue.
Read More: Stock Market Updates: Sensex Down 100 Points, Nifty Above 24,800; NTPC, Power Grid Up 2% Each
Akums Drugs IPO subscription status
By 11:27 AM on day one of bidding, the book build issue had been booked 0.30 times, the retail portion had been subscribed 1.10 times, and the NII portion had been booked 0.36 times.
Akums Drugs IPO Price Band
The company’s main board IPO has a fixed price band of Rs 646 to Rs 679 per equity share
Akums Drugs IPO Date
The initial offer has opened today and will remain open till 1 August 2024.
Akums Drugs IPO size
The company aims to raise Rs 1,856.74 crore, of which Rs 1,176.74 crore is reserved for the Offer for Sale (OFS) route.
Akums Drugs IPO lot size
A bidder can apply for lots, and one lot comprises 22 company shares.
Akums Drugs IPO allotment date
Share allocation after the IPO bidding closes, can be expected on Friday, 2nd August 2024.
Read More: Stocks To Watch: Tata Steel, IOC, RVNL, ACC, GAIL, PNB Housing, Varun Beverages, And Others
Akums Drugs IPO listing date
In the wake of the ‘T+3’ listing rule, we can expect Akums Drugs IPO listing on Tuesday, 6 August 2024.
What is the objective of Akums Drugs and Pharma IPO?
The net proceeds of the IPO will be utilized towards repayment of debt of the company and its subsidiaries, funding incremental working capital requirements, pursuing inorganic growth initiatives through acquisitions and general corporate purposes.
Akums Drugs is a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. The company is also engaged in the sale of branded pharmaceutical formulations and manufacturing of active pharmaceutical ingredients.
ICICI Securities, Axis Bank, Citigroup Global Markets India, and Ambit Private are the book-running lead managers, while Link Intime India is the registrar for the issue.
Read More: Ceigall India’s ₹1,253-crore IPO to open on August 1: Price band at ₹380-401
What is the current GMP of Akums Drugs and Pharma?
According to market analysts, the current GMP of Akums Drugs and Pharma is Rs 180 in the unlisted market, indicating a premium of 26% to the issue price.
Should You Invest?
“The company’s put call liabilities for recent new contracts adjustments were mandated under GAAP measures due to the lack of additional funding support. Based on restated financial data, although the issue pricing seems aggressive, this perception changes if we exclude such accounting provisions,” said the broking house Anand Rathi in a research report.
Giving a ‘buy’ tag to the public issue, Arun Kejriwal, Founder of Kejriwal Research and Investment Services, said, “The company is in the CDMO business, and it is utilizing its maximum capacity. The company is keeping its buffer ahead of the order book, which is also good. The company has higher provisioning in the balance sheet, so its profitability looks small. If we leave the provisioning aside, the valuations of the public offer look attractive. One can apply for the Akums Drugs IPO for list gain.”
DISCLAIMER:Disclaimer: The views and investment tips by experts in this News18.com report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions.
